TOI
Oncology InstituteCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
Current thesis
Material positive clinical data or realization of collaboration milestones without dilution would likely re-rate TOI sharply versus current levels; limited float and event leverage could amplify gains.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.2.
What can break
Inability to collect partner milestones, coupled with a dilutive equity raise while clinical progress is slow, would likely drive the stock toward low-penny territory or trigger trading suspension scenarios.
Momentum
96
Value
36
Sentiment
15
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.36 · Bull $1.20 · Bear $0.12
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.60
Why
Momentum96 · Δ7d +4.2
Value36 · Δ7d -0.0
Sentiment15 · Δ7d 0.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
96
34% active weight
Current posture
7d trendFlat
Δ7d
+4.2
Δ21d
+11.5
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
15
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade C. Momentum 96.1 / Value 36.4 / Sentiment 14.7
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$458.92M
Beta
0.17
Shares Out
98.38M
P/E (TTM) · Derived
-6.6
P/S (TTM)
0.84
P/FCF (TTM) · Derived
-14.55
Rev YoY
+36.7%
EPS YoY
+19.3%
Gross Margin
+14.8%
Op Margin
-8.9%
Net Debt
$43.46M
Current Ratio
1.68
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology